Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer

Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the appointment of Michelle Mahler, M.D., as Chief Medical Officer, effective March 1, 2024. Michelle will succeed Henry Adewoye, M.D., who is leaving Compugen to pursue other opportunities effective February 29, 2024, after 6 years with Compugen.

Related Keywords

South Africa ,Tel Aviv ,Israel ,Memorial Sloan Kettering Cancer Center ,New York ,United States ,New York Presbyterian Hospital ,San Francisco ,California ,Yvonne Naughton ,Weill Cornell ,Nasdaq ,Momenta Pharmaceuticals Inc ,Corporate Communications ,Therapeutics Inc ,Johnson ,Stock Exchange ,Clinical Development ,Gilead Sciences ,University Of The Witwatersrand ,Astrazeneca ,Compugen Ltd ,Mount Sinai Medical Center ,Compugen ,Aummune Therapeutics Ltd ,Chief Medical Officer ,Anat Cohen Dayag ,Chief Executive Officer ,Vice President ,Momenta Pharmaceuticals ,New York Presbyterian ,Columbia Presbyterian ,Investor Relations ,Michelle Mahler ,Michelle ,Henry Adewoye ,Clinical Stage ,Development Company ,